FindTrial
Sign In

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

COVID Vaccine VAC31518 Pre-approval Access Study

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04817657
Enrollment
Unknown
Registered
2021-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this Pre-approval access (PAA) program is to provide VAC31518 (Ad26.CoV2.S) vaccine for the prevention of coronavirus disease-2019 (COVID-19) infection. This PAA program may be considered to protect participants against a serious/life-threatening diseases or conditions, where there are no alternative treatments available.

Interventions

BIOLOGICALAd26.COV2.S

Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1\*10\^11 virus particles per milliliter (vp/ml) as intramuscular injection.

Sponsors

Janssen Research & Development, LLC
Lead SponsorINDUSTRY

Eligibility

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026